New Three-Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements in...

cafead

Administrator
Staff member
  • cafead   Apr 29, 2022 at 10:33: AM
via
  • 91% of infants treated with Evrysdi in the FIREFISH study were still alive at three years
  • Infants treated with Evrysdi maintained or continued to improve in measures of motor function, including their ability to sit without support for 5 and 30 seconds
  • Evrysdi has proven efficacy in infants and adults, with more than 5,000 patients treated to date

article source